{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Count of subjects with incidences of adverse events.","groups":[{"description":"Weeks 1 and 3: CRS-207 (1 × 10\\^9 CFU)\n\nWeeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m\\^2) and cisplatin (75 mg/m\\^2)\n\nWeeks 23 and 26: CRS-207\n\nMaintenance Vaccinations: CRS-207 every 8 weeks (starting at Week 34) until disease progression\n\nImmunotherapy plus chemotherapy: live attenuated double deleted Lm","id":"OG000","title":"Immunotherapy Plus Chemotherapy"},{"description":"Weeks 1 and 3: cyclophosphamide (200 mg/m\\^2), CRS-207 (1 × 10\\^9 CFU)\n\nWeeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m\\^2) and cisplatin (75 mg/m\\^2)\n\nWeeks 23 and 26: cyclophosphamide one day before CRS-207\n\nMaintenance Vaccinations: cyclophosphamide one day before CRS-207 every 8 weeks (starting at Week 34) until disease progression\n\nImmunotherapy with cyclophosphamide plus chemotherapy: live attenuated double deleted Lm","id":"OG001","title":"Immunotherapy With Cyclophosphamide Plus Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set (all participants who received \\>= 1 dose of study treatment)","reportingStatus":"POSTED","timeFrame":"From first study dose until 28 days after the final dose (an average of 44 weeks)","title":"Number of Subjects Reporting Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}